Copyright
©The Author(s) 2019.
World J Gastroenterol. Jun 14, 2019; 25(22): 2743-2751
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2743
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2743
Study | Period | Sample size | Selected group | Amount of IBL | Patients received BTF | Adverse effect of BTF on prognosis | Adverse effect of IBL on prognosis |
Dhar et al[7], 2000 | 1979-1989 | 152 | T2N0–T3N2 | > 500 ml | Not specified | - | Yes (Survival) |
Kamei et al[14], 2009 | 1992-2003 | 146 | Curative Gastrectomy | ≥ 475 mL | Included (13%) | No (Peritoneal recurrence) | Yes (Peritoneal recurrence) |
Liang et al[8], 2013 | 2003-2007 | 845 | stage I-III | ≥ 200 ml | Included (25%) | No (Survival) | Yes (Survival) |
Ishino et al[18], 2014 | 2001-2012 | 214 | Laparoscopic,stage I-II | ≥ 1% body weight | 0% | - | Yes (Survival) |
Arita et al[15], 2015 | 1997-2012 | 540 | Curative Gastrectomy | > 326 ml | Not specified | - | Yes (Peritoneal recurrence) |
Mizuno et al[9], 2016 | 1999-2015 | 203 | stage II/III | ≥ 400 mL | Not specified | - | Yes (Survival, Recurrence) |
Ito et al[10], 2018 | 2010-2014 | 1013 | stage II/III | > 330 mL | Not specified | - | Yes (Recurrence) |
Ojima et al[19], 2009 | 1991-2002 | 856 | Curative gastrectomy | ≥ 1000 mL | Included (18%) | Yes (Survival) | No (Survival) |
Squires et al[20], 2015 | 2000-2012 | 765 | Curative gastrectomy | > 250 mL | Included (22%) | Yes (Survival, Recurrence) | No (Survival, Recurrence) |
Kanda et al[6], 2016 | 1999-2014 | 250 | stage II/III | ≥ 800 mL | Included (23%) | Yes (Survival, Recurrence) | No (Survival) |
Study | Period | Sample size | Selected group | Rates of received BTF | Timing of transfusions | Adverse effect of BTF on prognosis |
Kaneda et al[44], 1987 | 1976-1980 | 231 | Not specified | 51% | Not specified | Yes (Survival) |
Ojima et al[19], 2009 | 1991-2002 | 856 | Curative gastrectomy | 18% | Pre + Intra + Post | Yes (Survival) |
Squires et al[20], 2015 | 2000-2012 | 765 | Curative gastrectomy | 22% | Intra + Post | Yes (Survival, Recurrence) |
Kanda et al[6], 2016 | 1999-2014 | 250 | stage II /III | 23% | Pre + Intra + Post | Yes (Survival, Recurrence) |
Kampschoer et al[45], 1989 | 1976-1981 | 1000 | Curative gastrectomy | 37% | Pre + Intra + Post | No (Survival) |
Kamei et al[14], 2009 | 1992-2003 | 146 | Curative gastrectomy | 13% | Not specified | No (Peritoneal recurrence) |
Pacelli et al[46], 2011 | 1990-2005 | 927 | Curative gastrectomy | 35% | Pre + Intra + Post | No (Survival) |
Liang et al[8], 2013 | 2003-2007 | 845 | stage I-III | 25% | Pre + Intra + Post | No (Survival) |
Rausei et al[47], 2013 | 1995-2011 | 224 | stage I-III | 20% | Pre + Intra + Post | No (Survival) |
Study | Rate of received | Adverse effect on OS | Adverse effect on CSS | Adverse effect on RFS | Adverse effect on PCs |
BTF patients | |||||
Sun et al[1], 2015 | 36.3% | Yes, | Yes, | Yes, | Not specified |
HR, 2.17; | HR, 2.57; | HR, 1.52; | |||
95%CI, 1.86-2.37 | 95%CI, 1.24-5.34 | 95%CI, 1.08-2.15 | |||
Li et al[2], 2015 | 44.8% | Yes, | Not specified | Yes, | Yes, |
HR, 1.26; | |||||
HR, 1.36; | HR, 3.33; | ||||
95 % CI, 1.21-1.31 | |||||
95%CI, 1.02-1.81 | 95%CI, 1.02-1.81 | ||||
Agnes et al[3], 2018 | Not specified | Yes, | Yes, | Yes, | Yes, |
HR, 1.34; | HR, 1.66; | HR, 1.48; | HR, 1.36; | ||
95%CI, 1.23-1.45 | 95%CI, 1.50-2.19 | 95%CI, 1.18-1.86 | 95%CI, 2.10-5.29 |
- Citation: Nakanishi K, Kanda M, Kodera Y. Long-lasting discussion: Adverse effects of intraoperative blood loss and allogeneic transfusion on prognosis of patients with gastric cancer. World J Gastroenterol 2019; 25(22): 2743-2751
- URL: https://www.wjgnet.com/1007-9327/full/v25/i22/2743.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i22.2743